<DOC>
	<DOCNO>NCT01535495</DOCNO>
	<brief_summary>This study investigate oral beta antagonist propranolol induce regression retinal neovascularization associate proliferative diabetic retinopathy .</brief_summary>
	<brief_title>Propranolol Diabetic Retinopathy</brief_title>
	<detailed_description>Oral propranolol 120mg daily give 10 patient proliferative diabetic retinopathy 12 week period evaluate effect retinal neovascularization .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Age &gt; =18 year Eyes proliferative diabetic retinopathy neovascularization Eyes history panretinal photocoagulation treatment persistent neovascularization deem investigator potential threat visual acuity either cause vitreous hemorrhage tractional retinal detachment . ( Group 1 maximum 5 eye enrol characteristic ) Eyes without history panretinal photocoagulation treatment , highrisk proliferative diabetic retinopathy characteristic ( i.e . eye early proliferative diabetic retinopathy yet highrisk vitreous hemorrhage tractional retinal detachment panretinal photocoagulation laser may defer ) . ( Group 2 maximum 5 eye enrol characteristic ) Either panretinal photocoagulation laser focal/grid laser study eye within 3 month study enrollment AntiVascular endothelial growth factor injection study eye within 3 month study enrollment Contraindications betablockers : allergy , previous intolerance , abnormally slow heart rate , asthma chronic obstructive pulmonary disease , use medication effect certain drug metabolic pathway may cause interaction . Known coronary arterial disease leave ventricular dysfunction , know peripheral vascular disease Resting heart rate &lt; 60 systolic blood pressure &lt; 90 and/or diastolic blood pressure &lt; 50 Pregnancy All patient either postmenopausal , adequate birth control , childbearing age , urinary pregnancy test perform Allergy fluorescein dye Media opacity obscure adequate determination neovascularization include dense cataract dense vitreous hemorrhage Patient already take oral betablocker Vulnerable population prisoner minor also exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>beta-antagonist</keyword>
	<keyword>propranolol</keyword>
	<keyword>diabetic retinopathy</keyword>
	<keyword>diabetes</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>neovascularization</keyword>
</DOC>